OCUL Quote, Financials, Valuation and Earnings

Axsome Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of -48.92%. Ocular Therapeutix's return on equity of -56.05% beat Axsome Therapeutics's return on equity of -309.19%.

Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 150%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.35 which suggests that it could grow by 66.89%. Given that Ocular Therapeutix has higher upside potential than Axsome Therapeutics, analysts believe Ocular Therapeutix is more attractive than Axsome Therapeutics.

Ocular Therapeutix has a beta of 1.508, which suggesting that the stock is 50.759% more volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $10.7M, which are smaller than Axsome Therapeutics quarterly revenues of $121.5M. Ocular Therapeutix's net income of -$64.1M is lower than Axsome Therapeutics's net income of -$59.4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.67x versus 11.81x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Editas Medicine has a net margin of -598.74% compared to Ocular Therapeutix's net margin of -1633.49%. Ocular Therapeutix's return on equity of -56.05% beat Editas Medicine's return on equity of -139.77%.

Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 150%. On the other hand Editas Medicine has an analysts' consensus of $3.38 which suggests that it could grow by 125%. Given that Ocular Therapeutix has higher upside potential than Editas Medicine, analysts believe Ocular Therapeutix is more attractive than Editas Medicine.

Ocular Therapeutix has a beta of 1.508, which suggesting that the stock is 50.759% more volatile than S&P 500. In comparison Editas Medicine has a beta of 2.149, suggesting its more volatile than the S&P 500 by 114.892%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $10.7M, which are larger than Editas Medicine quarterly revenues of $4.7M. Ocular Therapeutix's net income of -$64.1M is higher than Editas Medicine's net income of -$76.1M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.67x versus 3.46x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -598.74% compared to Ocular Therapeutix's net margin of -1036.46%. Ocular Therapeutix's return on equity of -56.05% beat Ocugen's return on equity of -215.5%.

Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 150%. On the other hand Ocugen has an analysts' consensus of $6.50 which suggests that it could grow by 825.27%. Given that Ocugen has higher upside potential than Ocular Therapeutix, analysts believe Ocugen is more attractive than Ocular Therapeutix.

Ocular Therapeutix has a beta of 1.508, which suggesting that the stock is 50.759% more volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $10.7M, which are larger than Ocugen quarterly revenues of $1.5M. Ocular Therapeutix's net income of -$64.1M is lower than Ocugen's net income of -$15.4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.67x versus 43.44x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of 4.19%. Ocular Therapeutix's return on equity of -56.05% beat TG Therapeutics's return on equity of 19.78%.

Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 150%. On the other hand TG Therapeutics has an analysts' consensus of $43.50 which suggests that it could grow by 30.36%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.

Ocular Therapeutix has a beta of 1.508, which suggesting that the stock is 50.759% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.208, suggesting its more volatile than the S&P 500 by 120.838%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $10.7M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Ocular Therapeutix's net income of -$64.1M is lower than TG Therapeutics's net income of $5.1M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 139.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.67x versus 13.89x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.